Does CASR rs1801725 GT shift calcium regulation upward and affect renal-mineral handling?

The CASR gene encodes the calcium-sensing receptor (CaSR), a G-protein-coupled receptor highly expressed in the parathyroid glands and renal tubules that serves as the master regulator of systemic calcium homeostasis. The rs1801725 polymorphism directly influences this homeostatic feedback loop, carrying distinct implications for systemic calcium levels and kidney function.

Mechanistic pathways of the rs1801725 variant

• Receptor desensitization: The rs1801725 (G>T) variant causes an alanine-to-serine substitution at codon 986 (A986S) within the intracellular C-terminal tail of the CaSR. This structural alteration reduces the receptor's sensitivity to extracellular calcium.
• Upward setpoint shift: Because of this blunted sensitivity, higher circulating calcium concentrations are required to trigger downstream signaling. In heterozygous GT carriers, this manifests as an intermediate phenotype characterized by modestly elevated serum total and ionized calcium levels, while basal parathyroid hormone (PTH) levels typically remain within normal limits due to homeostatic compensation.

Implications for renal-mineral handling and stone risk

• Altered renal excretion: In the renal tubules, the less sensitive CaSR alters normal tubular calcium reabsorption. This impairment can lead to increased urinary calcium excretion, particularly in individuals with existing metabolic predispositions.
• Nephrolithiasis susceptibility: Carriers of the T allele (GT and TT genotypes) exhibit an increased risk of hypercalciuria. Elevated urinary calcium levels promote the supersaturation of calcium salts and subsequent intratubular crystal formation, translating to a higher clinical susceptibility to calcium-based kidney stones (nephrolithiasis).

Bottom line

• The CASR rs1801725 GT genotype reduces calcium-sensing receptor sensitivity, shifting the physiological calcium setpoint upward and altering renal calcium reabsorption. This genetic profile elevates the risk of hypercalciuria and kidney stones, making the monitoring of serum and urinary mineral parameters clinically valuable, particularly in individuals with a history of stone disease.